| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
101,390,000 |
| Market
Cap: |
1.47(B) |
| Last
Volume: |
668,805 |
Avg
Vol: |
666,923 |
| 52
Week Range: |
$11.4 - $16.78 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Innoviva is a company with a portfolio of royalties and other healthcare assets. Co.'s royalty portfolio contains respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR®/BREO® ELLIPTA®, ANORO® ELLIPTA® and TRELEGY® ELLIPTA®. Co. is entitled to royalty payments made by GSK under its agreements that assigned to Theravance Respiratory Company, LLC (TRC), including TRELEGY® ELLIPTA® and any other product or combination of products that may be discovered or developed in the future under the Long-Acting Beta2 Agonist Collaboration Agreement and the Strategic Alliance Agreement with GSK, which have been assigned to TRC other than RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
661,000 |
664,000 |
| Total Buy Value |
$0 |
$0 |
$8,435,402 |
$8,468,005 |
| Total People Bought |
0 |
0 |
1 |
2 |
| Total Buy Transactions |
0 |
0 |
11 |
12 |
| Total Shares Sold |
0 |
10,994 |
10,994 |
10,994 |
| Total Sell Value |
$0 |
$153,810 |
$153,810 |
$153,810 |
| Total People Sold |
0 |
1 |
1 |
1 |
| Total Sell Transactions |
0 |
1 |
1 |
1 |
| End Date |
2024-01-18 |
2023-10-17 |
2023-04-18 |
2022-04-18 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Sarissa Capital Management Lp |
|
• • • |
2023-05-30 |
4 |
B |
$13.01 |
$1,560,648 |
I/I |
120,000 |
7,200,000 |
0.01 |
3% |
|
| Sarissa Capital Management Lp |
|
• • • |
2023-05-26 |
4 |
B |
$13.12 |
$393,729 |
I/I |
30,000 |
7,080,000 |
0.01 |
1% |
|
| Sarissa Capital Management Lp |
|
• • • |
2023-05-25 |
4 |
B |
$13.09 |
$654,330 |
I/I |
50,000 |
7,050,000 |
0.01 |
-0% |
|
| Schlesinger Sarah J. |
Director |
– • – |
2023-05-22 |
4 |
A |
$0.00 |
$0 |
D/D |
16,495 |
104,706 |
|
- |
|
| Dipaolo Mark |
Director |
– • – |
2023-05-22 |
4 |
A |
$0.00 |
$0 |
D/D |
16,495 |
104,706 |
|
- |
|
| Srivastava Sapna |
Director |
– • – |
2023-05-22 |
4 |
A |
$0.00 |
$0 |
D/D |
16,495 |
30,173 |
|
- |
|
| Birx Deborah |
Director |
– • – |
2023-05-22 |
4 |
A |
$0.00 |
$0 |
D/D |
16,495 |
58,984 |
|
- |
|
| Haimovitz Jules |
Director |
– • – |
2023-05-22 |
4 |
A |
$0.00 |
$0 |
D/D |
16,495 |
116,906 |
|
- |
|
| Kostas Odysseas D |
Director |
– • – |
2023-05-22 |
4 |
A |
$0.00 |
$0 |
D/D |
16,495 |
108,702 |
|
- |
|
| Zhen Marianne |
Chief Accounting Officer |
• • – |
2023-05-19 |
4 |
D |
$13.47 |
$10,560 |
D/D |
(784) |
51,937 |
|
- |
|
| Sarissa Capital Management Lp |
|
• • • |
2023-05-19 |
4/A |
B |
$13.48 |
$485,147 |
I/I |
36,000 |
7,000,000 |
0.01 |
- |
|
| Sarissa Capital Management Lp |
|
• • • |
2023-05-18 |
4 |
B |
$13.05 |
$130,538 |
I/I |
10,000 |
6,964,000 |
0.01 |
-0% |
|
| Sarissa Capital Management Lp |
|
• • • |
2023-05-18 |
4/A |
B |
$13.05 |
$130,538 |
I/I |
10,000 |
6,964,000 |
0.01 |
- |
|
| Sarissa Capital Management Lp |
|
• • • |
2023-05-17 |
4 |
B |
$13.07 |
$653,690 |
I/I |
50,000 |
6,954,000 |
0.01 |
0% |
|
| Sarissa Capital Management Lp |
|
• • • |
2023-05-17 |
4/A |
B |
$13.07 |
$653,690 |
I/I |
50,000 |
6,954,000 |
0.01 |
- |
|
| Zhen Marianne |
Chief Accounting Officer |
• • – |
2023-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
1,576 |
52,721 |
|
- |
|
| Sarissa Capital Management Lp |
|
• • • |
2023-05-11 |
4 |
B |
$12.34 |
$3,577,411 |
I/I |
290,000 |
6,904,000 |
0.01 |
3% |
|
| Sarissa Capital Management Lp |
|
– – • |
2023-05-09 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
6,614,000 |
|
8% |
|
| Zhen Marianne |
Chief Accounting Officer |
• • – |
2023-04-13 |
4 |
A |
$0.00 |
$0 |
D/D |
14,344 |
51,145 |
|
- |
|
| Raifeld Pavel |
Chief Executive Officer |
• – – |
2023-03-10 |
4 |
B |
$10.87 |
$32,603 |
D/D |
3,000 |
9,799 |
2.74 |
17% |
|
| Zhen Marianne |
Chief Accounting Officer |
• – – |
2023-02-17 |
4 |
D |
$12.42 |
$23,002 |
D/D |
(1,852) |
36,801 |
|
- |
|
| Zhen Marianne |
Chief Accounting Officer |
• – – |
2022-11-18 |
4 |
D |
$13.55 |
$11,219 |
D/D |
(828) |
38,653 |
|
- |
|
| Zhen Marianne |
Chief Accounting Officer |
• – – |
2022-11-15 |
4 |
A |
$0.00 |
$0 |
D/D |
433 |
39,481 |
|
- |
|
| Zhen Marianne |
Chief Accounting Officer |
• – – |
2022-08-19 |
4 |
D |
$14.12 |
$11,720 |
D/D |
(830) |
39,048 |
|
- |
|
| Zhen Marianne |
Chief Accounting Officer |
• – – |
2022-05-20 |
4 |
D |
$16.29 |
$13,488 |
D/D |
(828) |
39,878 |
|
- |
|
37 Records found
|
|
Page 1 of 2 |
|
|
0.07 (0.49%) 
